# Layered Management of Hypertrophic Scars and Keloids: From Silicone and Intralesional Triamcinolone Acetonide Plus 5-Fluorouracil to Adjuvant Strontium-90

**Authors:** Osama S Abbadi, Faris Abdon, Zuhoor S Othman, Khalid Abdel Aziz

PMC · DOI: 10.7759/cureus.101893 · Cureus · 2026-01-20

## TL;DR

This paper reviews layered treatment strategies for hypertrophic scars and keloids, emphasizing early silicone use and combination therapies for better outcomes.

## Contribution

The paper provides a pragmatic, evidence-based algorithm for layered treatment of fibroproliferative scars based on lesion characteristics and patient factors.

## Key findings

- Silicone gel or sheets are most effective for early scar prevention and treatment.
- Combining triamcinolone acetonide with 5-fluorouracil improves flattening and symptom control compared to steroids alone.
- Strontium-90 brachytherapy may be used as consolidation or postoperative adjuvant for selected thin keloids.

## Abstract

Hypertrophic scars and keloids are fibroproliferative scars that can cause disfigurement, pruritus, pain, contracture, and reduced quality of life. Outcomes remain inconsistent because phenotypes vary by anatomic site, thickness, skin type, and time since injury, and no single modality is uniformly curative. We performed a narrative review informed by a structured search of MEDLINE/PubMed, Embase, Cochrane Library, Web of Science, and Scopus (2000 to November 2025), including clinical trials, observational studies, systematic reviews, and consensus guidance with clinically actionable treatment parameters. Evidence most consistently supports early, low-risk modulation with silicone gel or sheets for the prevention and early treatment of hypertrophic scars. For established hypertrophic scars and keloids, intralesional triamcinolone acetonide combined with 5-fluorouracil provides a practical pharmacological backbone, offering more reliable flattening and symptom control than steroid monotherapy. Adjuncts should be selected according to dominant clinical features, including cryotherapy for relatively thin lesions, fractional carbon dioxide laser for thickness and texture, and botulinum toxin A when tension, pruritus, or contracture is prominent. For selected thin keloids, radiotherapy options include external beam techniques and brachytherapy; superficial beta-brachytherapy with strontium-90 may serve as consolidation after response to intralesional therapy or as targeted postoperative adjuvant at high-risk sites. Because pigmentary adverse effects are clinically important in darker skin types, procedural choices should incorporate explicit counseling and conservative parameters. A pragmatic algorithm, reassessment triggers, and a modality summary table are provided to support routine clinical decision-making.

## Linked entities

- **Chemicals:** triamcinolone acetonide (PubChem CID 6436), 5-fluorouracil (PubChem CID 3385), strontium-90 (PubChem CID 5486204)

## Full-text entities

- **Genes:** DPT (dermatopontin) [NCBI Gene 1805] {aka TRAMP}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** pigmentation (MESH:D010859), HS (MESH:C567159), atrophy (MESH:D001284), pain (MESH:D010146), hypopigmentation (MESH:D017496), PIH (MESH:D017495), inflammation (MESH:D007249), tension (MESH:D018781), trauma (MESH:D014947), telangiectasia (MESH:D013684), Pruritus (MESH:D011537), contracture (MESH:D003286), burn (MESH:D002056), VSS (MESH:D002921), toxicity (MESH:D064420), erosions (MESH:D014077), ulceration (MESH:D014456), Fitzpatrick skin types IV-VI (MESH:C000631847), Keloids (MESH:D007627), hypertrophy (MESH:D006984), Hypertrophic Scars (MESH:D017439), rigidity (MESH:D009127), erythema (MESH:D004890)
- **Chemicals:** triamcinolone (MESH:D014221), hyaluronic acid (MESH:D006820), Silicone (MESH:D012828), Ir-192 (MESH:C000615087), Sr-90 (MESH:C000615490), Ir- (MESH:D007495), 5-FU (MESH:D005472), ICG (MESH:D007208), Sr-90Y (-), TAC (MESH:D014222), Imiquimod (MESH:D000077271), steroid (MESH:D013256), CO2 (MESH:D002245)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12918423/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12918423/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12918423/full.md

---
Source: https://tomesphere.com/paper/PMC12918423